Mesenbio

Mesenbio is a preclinical-stage biopharmaceutical company developing a cell line platform that produces a consistent, scalable supply of therapeutic extracellular vesicles, addressing a key bottleneck limiting this treatment class.

The company's cells generate naturally bioactive vesicles with combined anti-inflammatory and regenerative potential, and its internal pipeline is focused on musculoskeletal disease, including a lead candidate targeting arthritic joint inflammation and damage.